Post Profile

EpiPen Maker Mylan Will Pay $465 Million to Settle Medicaid Overcharging Case

Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.
read more


Related Posts

EpiPen Maker Mylan To Pay $465 Million For Shifty Medicaid Billing Practices

News : Huffington Post

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether misclassification of its EpiPen emergency allergy treatment resulted in underpayment of rebates to the U.S. Medicaid healthcare program. ...

Mylan to pay $465M settlement over EpiPen

Business & Finance : USAToday: Money

EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices        

Mylan to pay $465 million over Medicaid pricing of EpiPen

Business & Finance : Mashable: Business

Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.  Mylan, which came under fire this summer for sys...

The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine

Business & Finance : Business Insider: Money Game

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...

Mylan to pay $465-million settlement over Medicaid EpiPen rebates

Business & Finance : LA Times: Business

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...


Copyright © 2016 Regator, LLC